Literature DB >> 30272277

Histone deacetylase HDAC4 promotes the proliferation and invasion of glioma cells.

Jun-Yan Cai1, Tong-Tong Xu2, Ye Wang2, Jing-Jian Chang3, Jian Li4, Xiao-Yang Chen3, Xi Chen3, Yi-Fei Yin3, Xue-Jun Ni3.   

Abstract

Glioma is the most lethal type of primary brain tumor characterized by aggressiveness and a poor prognosis. Histone deacetylase 4 (HDAC4) is frequently dysregulated in human malignancies. However, its biological functions in the development of glioma are not fully understood. The present study aimed to evaluate HDAC4 expression in human glioma and to elucidate the mechanistic role of HDAC4 in glioma. The results suggested that HDAC4 was significantly upregulated in glioma tissues and a number of glioma cell lines compared with adjacent non-tumor tissues and the non-cancerous human glial cell line SVG p12, respectively (P<0.05). The proliferation, adenosine triphosphate (ATP) levels and invasion ability were substantially enhanced in U251 cells with HDAC4 overexpression, and suppressed in U251 cells with a knockdown of HDAC4 compared with that in U251 cells transfected with the negative control. Knockdown of HDAC4 resulted in cell cycle arrest at the G0/G1 phase and induced the increase of reactive oxygen species level in U251 cells. Furthermore, HDAC4 overexpression was revealed to substantially inhibit the expression of cyclin-dependent kinase (CDK) inhibitors p21 and p27, and the expression of E-cadherin and β‑catenin in glioma U251 cells. Knockdown of HDAC4 substantially promoted the expression of CDK1 and CDK2 and vimentin in glioma U251 cells. Mechanistically, the results of the present study demonstrated that HDAC4 displayed a significant upregulation in glioma, and promoted glioma cell proliferation and invasion mediated through the repression of p21, p27, E-cadherin and β‑catenin, and the potentiation of CDK1, CDK2 and vimentin. Altogether, the present study revealed that HDAC4 overexpression was central for the tumorigenesis of glioma, which may serve as a useful prognostic biomarker and potential therapeutic target for glioma.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30272277     DOI: 10.3892/ijo.2018.4564

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  14 in total

Review 1.  Regulation of Central Nervous System Development by Class I Histone Deacetylases.

Authors:  Santosh R D'Mello
Journal:  Dev Neurosci       Date:  2020-01-24       Impact factor: 2.984

2.  Neuroprotection of Bone Marrow-Derived Mesenchymal Stem Cell-Derived Extracellular Vesicle-Enclosed miR-410 Correlates with HDAC4 Knockdown in Hypoxic-Ischemic Brain Damage.

Authors:  Mingqi Shen; Rongxiu Zheng; Xuan Kan
Journal:  Neurochem Res       Date:  2022-08-26       Impact factor: 4.414

3.  Deacetylation of Glutaminase by HDAC4 contributes to Lung Cancer Tumorigenesis.

Authors:  Tao Wang; Zhuo Lu; Tianyu Han; Yanan Wang; Mingxi Gan; Jian-Bin Wang
Journal:  Int J Biol Sci       Date:  2022-07-04       Impact factor: 10.750

4.  Knockdown of CircCRIM1 Inhibits HDAC4 to Impede Osteosarcoma Proliferation, Migration, and Invasion and Facilitate Autophagy by Targeting miR-432-5p.

Authors:  Jun Liu; Guang Feng; Zhengwei Li; Rui Li; Peng Xia
Journal:  Cancer Manag Res       Date:  2020-10-15       Impact factor: 3.989

5.  Long non-coding RNA GAS5 suppresses rheumatoid arthritis progression via miR-128-3p/HDAC4 axis.

Authors:  Tao Peng; Dehui Ji; Yankai Jiang
Journal:  Mol Cell Biochem       Date:  2021-02-20       Impact factor: 3.396

6.  LPS-treatment of bovine endometrial epithelial cells causes differential DNA methylation of genes associated with inflammation and endometrial function.

Authors:  Naveed Jhamat; Adnan Niazi; Yongzhi Guo; Metasu Chanrot; Elena Ivanova; Gavin Kelsey; Erik Bongcam-Rudloff; Göran Andersson; Patrice Humblot
Journal:  BMC Genomics       Date:  2020-06-03       Impact factor: 3.969

7.  Hsa_circ_0003258 promotes prostate cancer metastasis by complexing with IGF2BP3 and sponging miR-653-5p.

Authors:  Yu-Zhong Yu; Dao-Jun Lv; Chong Wang; Xian-Lu Song; Tao Xie; Tao Wang; Zhi-Min Li; Jia-Ding Guo; Du-Jiang Fu; Kang-Jin Li; Ding-Lan Wu; Franky Leung Chan; Ning-Han Feng; Zhe-Sheng Chen; Shan-Chao Zhao
Journal:  Mol Cancer       Date:  2022-01-05       Impact factor: 27.401

8.  Senescence marker protein 30 inhibits tumor growth by reducing HDAC4 expression in non-small cell lung cancer.

Authors:  Changjian Shao; Kai Guo; Liqun Xu; Yimeng Zhang; Hongtao Duan; Yingtong Feng; Minghong Pan; Di Lu; Xiaoya Ren; Apar Kishor Ganti; Taiki Hakozaki; Jing Han; Xiaolong Yan; Zhiqiang Ma
Journal:  Transl Lung Cancer Res       Date:  2021-12

9.  Expression and prognostic analyses of HDACs in human gastric cancer based on bioinformatic analysis.

Authors:  Luting Chen; Yuchang Fei; Yurong Zhao; Quan Chen; Peifeng Chen; Lei Pan
Journal:  Medicine (Baltimore)       Date:  2021-07-09       Impact factor: 1.817

10.  In silico Design of Novel Histone Deacetylase 4 Inhibitors: Design Guidelines for Improved Binding Affinity.

Authors:  Shana V Stoddard; Kyra Dodson; Kamesha Adams; Davita L Watkins
Journal:  Int J Mol Sci       Date:  2019-12-28       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.